$15 seems reasonable. Would the Harvster let her go for a measly $1.6 bil? My opinion is that Mrk is obviously our best suitor. A 534 collaboration with another pharma might cloud things a bit.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.